These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1482938)

  • 21. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment.
    Di Paolo B; Di Liberato L; Fiederling B; Catucci G; Bucciarelli S; Paolantonio L; Albertazzi A
    ASAIO J; 1992; 38(3):M477-80. PubMed ID: 1457906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Early efficacy of recombinant human erythropoietin in treatment of anemia].
    Huang S; Yang L; Huang M
    Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):317-9. PubMed ID: 9389072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aluminium interference in the treatment with recombinant human erythropoietin.
    Casati S; Campise M; Ponticelli C
    Contrib Nephrol; 1990; 87():87-94. PubMed ID: 2093544
    [No Abstract]   [Full Text] [Related]  

  • 27. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
    Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
    Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
    Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does anemia correction by rHuEPO improve uremic cardiopathy?
    Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
    Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
    Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
    J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human erythropoietin therapy. Part I: clinical issues.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):1-34. PubMed ID: 2928605
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
    Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
    Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment.
    Wiecek A; Kokot F; Marcinkowski W
    Nephron; 1995; 69(4):489-90. PubMed ID: 7777122
    [No Abstract]   [Full Text] [Related]  

  • 36. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
    Zehnder C; Blumberg A
    Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
    Nissenson AR
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.